echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > NEJM: For the treatment of type 2 diabetes, Tirzepatide is better than Semaglutide!

    NEJM: For the treatment of type 2 diabetes, Tirzepatide is better than Semaglutide!

    • Last Update: 2021-07-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Diabetes is one of the leading causes of death in the world.
    According to data from the International Diabetes Federation (IDF) in 2019, the number of people with diabetes worldwide will increase by 51% to 700 million by 2045
    .


    Diabetes patients rarely recover through drug therapy, and most patients can only control their blood sugar through drugs


    Diabetes is one of the leading causes of death in the world.


     Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist, which is being developed for the treatment of type 2 diabetes
    .


    GLP-1 receptor agonist Suoma Lu peptide was previously approved for 2 type diabetes treatment


     Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist, which is being developed for the treatment of type 2 diabetes


     A recent phase 3 trial study published in NEJM showed that in patients with type 2 diabetes, tirzepatide is not inferior to and superior to semaglutide in terms of the average change in glycosylated hemoglobin levels from baseline to 40 weeks


     

    In this 40-week open-label phase 3 trial, researchers randomly assigned 1879 patients to receive 5 mg, 10 mg, or 15 mg tirzepatide or doses at a 1:1:1:1 ratio Semaglutide is 1 mg
    .



    In this 40-week open-label phase 3 trial, researchers randomly assigned 1879 patients to receive 5 mg, 10 mg, or 15 mg tirzepatide or doses at a 1:1:1:1 ratio Semaglutide is 1 mg


    The results found, 5mg, 15mg, and 10 mg for glycated hemoglobin levels relative to baseline _epa peptide estimated average change of -2.


    The weight loss of tirzepatide was greater than that of semaglutide (the least squares mean estimated treatment difference was -1.


    The most common adverse events were gastrointestinal adverse events.


    Among patients receiving tirzepatide, 0.


    In summary, in patients with type 2 diabetes, tirzepatide is not inferior to and superior to semaglutide in terms of the average change in glycosylated hemoglobin levels from baseline to 40 weeks


    References: Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes June 25, 2021 DOI: 10.
    1056 / NEJMoa2107519 References: Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes June 25, 2021 DOI: 10.
    1056 / NEJMoa2107519 in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.